Wheeler Bio Raises $35M for 52,000-Square-Foot Manufacturing Facility

The company is eying a spot in the Oklahoma City Innovation District.

Wheeler Bio 19
Wheeler Bio

Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of antibody-based therapies, announced the closing of an oversubscribed Series A-1 financing round totaling $35 million.

Wheeler Bio is a CDMO built upon its scientific platform, Modular CMC. Along with supporting the ongoing success of clients, this financing will broaden Wheeler’s capabilities and pave the way for future growth – including planning the build-out of a 52,000-square-foot large-scale biologics manufacturing facility adjacent to a biomanufacturing workforce training center (BioTC) at Convergence in the Oklahoma City Innovation District.

"This investment accelerates Wheeler Bio’s growth and expands its ability to deliver high-quality CMC services for antibody-based therapies," said Errik Anderson, Founder and CEO of Alloy Therapeutics. "Alloy has supported Wheeler since its inception, and as the company has honed its overall strategy and advanced its cGMP capabilities under Patrick Lucy’s proven leadership, we are deepening our commitment. Wheeler has a clear path to expanded capabilities and large-scale production, we’re excited to continue supporting its growth and impact on drug development."

“Wheeler Bio is perfectly positioned to meet the growing demand for platforms that accelerate the transition from bench to bedside. We are excited for this collaboration so that Wheeler Bio can perform a crucial role in creating an infrastructure to support biotechnology companies that have innovative ideas significantly improving patient quality of life,” said Takahiro Tokuda, Healthcare Division COO, Mitsubishi Corporation.

More in Operations